Prior studies suggested levels of breast cancer-specific anti-TAA may be lower in current users of hormone therapy, especially estrogen [16], but we observed no confounding with current hormone use and our findings were similar when limited to ER-positive breast cancer cases. Here, ESR1 is linked to breast carcinoma.